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ABSTRACT. The use of functionalized magnetic particles is increasing thanks to their benefits, 
simplifying the analytical process, and great promising results obtained in a wide range of 
applications. Particularly, streptavidin-coated magnetic beads offer the possibility of a rapid and 
very efficient grafting of biomolecules. Unfortunately, current methods to control and compute 
such grafting process are cumbersome and scarce. Herein, we have developed a simple, rapid 
and reliable chemiluminescent assay to control the grafting rate of the functionalized magnetic 
beads. The power of the assay also relies on its ability to predict the required amount of ligands 
to obtain a precise grafting rate. In addition, results were correlated with a more general 
parameter in material functionalization characterization like the surface ligand density. Finally, 
the assay was validated for a wide variety of biotinylated biomolecules sizes, ranging from small 
molecules (around 200 Da) to antibodies (around 150 kDa). This approach will allow a precise 
quantification and prediction of the functionalization of the magnetic particles that is of 
enormous importance for quality control in many applications. 
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INTRODUCTION 
Controlling the grafting rate and the ligand surface density is a key parameter for further bio-
applications of functionalized particles. The number of molecules per particle is a vital piece of 
information largely pursued because will enable to the users the real control and design of 
quantitative in vitro and in vivo experiments1. This interest relies on the importance of these 
ligands in the final properties of the particles such as stability, reactivity, toxicity as well as in 
vivo (i.e. biodistribution, cellular uptake, clearance pathway, formation of the protein corona, 
etc.) or environmental behavior of the particles2-4. Indeed, ligand density and the control of the 
surface reactive functions are also used, among others, as quality control parameters in the 
development of nano-therapeutic products5,6.  
Despite the relevance of this kind of study, only few works are completely devoted to this end 
and sometimes this information is missed or not valorized, as it should be. Inductively coupled 
plasma mass spectrometry (ICP-MS)7-10 and optical emission spectrometry (ICP-OES)11, nuclear 
magnetic resonance spectroscopy (NMR)12, infrared spectroscopy (IR)6, microscale 
thermogravimetry analysis (TGA)13, X-ray photoelectron spectroscopy (XPS)14, and colorimetric 
or fluorimetric assays8,15, have been employed so far to characterize the particle surface 
coverage. In parallel, modeling approaches or theoretical calculations have been also developed 
either to confirm the experimental results and to predict the behavior or properties of the particle 
by modifying the ligand density or the environment of exposure16,17. Nevertheless, some of these 
strategies require sophisticated and expensive instrumentation, specialized user, and hard data 
treatment processes. Thus, simple, easy to use, and general approaches to achieve this important 
information are currently highly demanded. 
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Regarding the specific interaction of biotin-streptavidin, the strongest non-covalent interaction 
that exists, a few approaches have been developed to characterize the biotin-binding capacity of 
streptavidin-coated supports18-20. All these works are focused on the total number of available 
binding sites onto the support instead of on the grafting rate or the saturation rate by a given 
molecule. Finally, it should be noted that no general approach to evaluate and control the 
grafting rate of a streptavidin-coated support applicable to a wide range of biotinylated ligands 
sizes has been developed. 
Herein we propose a rapid, simple, low-sample consumption and reliable chemiluminescent 
test to predict and control the grafting rates of streptavidin-magnetic beads (MB) and the results 
have been correlated with a more general characterization parameter such as the ligand surface 
density. MB are selected as a model support since their use in bio-applications is nowadays 
increasing due to their benefits simplifying the analytical process (e.g. purification steps, time of 
analysis, etc) and the great promising results in a wide range of applications21,22. 
The robustness of the proposed methodology has been validated with a range of biotinylated 
biomolecules with different molecular weights and also tested for its predictive power by 
grafting with unknown biotinylated proteins.  
 
MATERIAL AND METHODS 
Chemicals and reagents 
Magnetic beads Dynabeads™ M-280 Streptavidin and magnetic supports DynaMag™-5 
Magnet and DynaMag™-96 Side Skirted Magnet were purchased from Invitrogen by Thermo 
Fisher Scientific (Eugene, OR, USA). Corning® Costar® 96-well White assay plates (high 
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binding and polystyrene flat bottom) were obtained from Sigma-Aldrich (Saint-Quentin 
Fallavier, France). 
Bovine Serum Albumin fraction IV (BSA) and Dulbecco's Phosphate Buffered Saline (PBS) 
were obtained from Eurobio (Les Ulis, France). Tween 20 and 4-nitrophenyl phosphate disodium 
salt hexahydrate (pNPP) were purchased from Sigma-Aldrich. Biotinylated peroxidase (bt-HRP) 
and Super Signal® West Pico Chemiluminescent Substrate (containing Stable Peroxide solution 
and Luminol Enhancer solution) were obtained from Thermo Fisher Scientific. 
Biotin and N-Biotinyl-NH(PEG)11-COOH (bt-polymer) were obtained from Sigma-Aldrich. 
Biotinylated TNF (bt-TNF), biotinylated VEGF165 (bt-VEGF165), biotinylated Goat IgG (bt-
Goat IgG) and biotinylated anti-Human Endoglin/CD105 Antibody (bt-anti hEndoglin IgG) were 
from R&D Systems (Bio-techne, Abingdon, UK). Biotinylated Bovine Serum Albumin (bt-BSA) 
was from Thermo Fisher Scientific and biotinylated oligonucleotide 80-mer was synthesized by 
Eurofins Genomics (Ebersberg, Germany). Finally, biotinylated VEGF95 (bt-VEGF95) and 
biotinylated peptides A and B (AC-14 and LW146-2, respectively) were homemade. 
 
Nomenclature 
Along this manuscript the following terms will be used to identify different status of beads: 
- Non-grafted beads are the naked beads  
- Saturated beads are the beads totally covered with any ligand 
- X% saturated beads are the beads partially covered with any ligand 
- Saturation rate (Sat. rate) is the percentage of bead surface covered by the ligand 
- Binding capacity is the inflexion point in the curves of saturation 
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Grafting of streptavidin-magnetic beads 
Dynabeads™ M-280 Streptavidin were functionalized with different biotinylated biomolecules 
as described in the provider datasheet23. Typically for functionalization of 0.12 mg of MB, the 
beads were re-suspended in the vial (vortexed for 30 s) and then 12 µL of stock solution were 
transferred to a tube. MB were washed two times with 200 µL of PBS and re-suspended at a 
concentration of 10 mg/mL in PBS. The calculated amount of the biotinylated molecule in PBS 
was added to MB and incubated for 1 h at room temperature using gentle rotation (300 rpm). 
Grafted beads were washed four times with 300 µL of PBS/0.1% BSA (w/v) and dispersed at the 
initial concentration of MB (10 mg/mL) in PBS/0.1% BSA and stored at 4°C until use. 
 
Consecutive grafting of streptavidin-magnetic beads 
The experimental procedure for consecutive grafting of MB was similar to the procedure used 
for grafting (see previous section). Practically, 12 μL of 10 mg/mL MB were first grafted with 
different molecules (i.e. biotin; bt-VEGF95; and bt-BSA) at different concentrations. After 
incubation, supernatants were taken and used to perform a second grafting of other fresh 12 μL 
of 10 mg/mL MB. After each incubation, MB were washed and stored at 4°C until use. 
 
Procedure of the bt-HRP assay 
A white high binding 96-well plate (Costar 3922) was blocked by adding 200 μL/well of 
blocking buffer (PBS containing 3% BSA) and incubating during 2 h at 37 ºC. The plate was 
then washed three times with 200 μL/well of PBS/0.1%Tween 20. Afterwards, 20 μL of the 
desired diluted grafted MB (beads dilution = 1:40) and 100 μL of diluted bt-HRP (15 nM) were 
added to each well (120 μL final volume). Both dilutions were done in PBS/0.05%Tween 20. 
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After 1 h incubation at 37 ºC, the plate was washed three times with 200 μL/well 
PBS/0.1%Tween 20. Then, 100 μL of chemiluminescent substrate (containing a solution of 
peroxide and luminol enhancer at 1:1, v:v) were added to each well. Immediately after the 
addition of the chemiluminescent substrate (5 min), chemiluminescent signal was measured on 
an Infinite F200 Pro Microplate Reader from TECAN (Männedorf, Switzerland). It is 
noteworthy that MB were fixed at the flat bottom of wells using a 96-well magnet plate both 
during washing steps and just before measuring the chemiluminescent signal. 
For each biotinylated molecule grafted onto MB, the Sat. rate (%) of grafted beads was 
calculated using the equation 1: 
 
𝑺𝒂𝒕𝒖𝒓𝒂𝒕𝒊𝒐𝒏 𝒓𝒂𝒕𝒆 (%) = [
𝑺𝒎𝒂𝒙−𝑺𝒊
𝑺𝒎𝒂𝒙−𝑺𝒔𝒂𝒕
] × 𝟏𝟎𝟎              Equation 1 
 
where Si is the measured signal for grafted beads, Smax is the maximum signal of the non-
grafted beads, and Ssat is the signal of 100% saturated beads (obtained with a large excess of 
ligand, approx. 2 times the binding capacity). All experiments were performed in triplicate, 
unless otherwise indicated. 
 
RESULTS AND DISCUSSION 
Development and optimization of bt-HRP assay 
Saturation rate and the number of ligands per particle are critical parameters for the correct 
design of magnetic particle-based quantitative bioassays. Thus, taking advantage of the use of 
streptavidin functionalized MB, we have developed an indirect bioassay based in the 
measurement of the free streptavidin sites onto the beads after conjugation of the target 
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biotinylated molecules (Figure 1). To do so, biotinylated horseradish peroxidase (bt-HRP) was 
used and the subsequent addition of its substrate (Luminol + H2O2) allows quantifying the free 
streptavidin sites by chemiluminescence. Non-grafted beads must be used as reference of the 
total sites available onto the beads. 
First of all, some parameters should be optimized: the amount of beads needed to perform the 
assays, the concentration of bt-HRP and the incubation time. Two first parameters are related and 
will be optimized to ensure the maximum signal of the assay while reducing the reagents 
consumption. In the optimization of the amount of beads it is also crucial to adapt the protocol 
for easy handling of the MB by the final users. Since it has been arbitrary chosen that 20 µL of 
beads and 100 µL of bt-HRP are added in each well, several beads dilutions have been tested 
ranging from 1:10 to 1:100. Dilution 1:40 of the stock solution of MB (10 mg/ml) has been 
selected as the best compromise between easy handling and beads consumption. More diluted 
solutions are difficult to handle, inducing loses of beads during the washing steps, while more 
concentrated ones require a large amount of beads and may disrupt the signal measurement. 
Finally, the selected 1:40 dilution resulted in a consumption of 5 µg of beads per well.  
Signal maximum of the assay was then optimized by adjusting the concentration of bt-HRP. 
For such purpose, a saturation curve of bt-HRP (0 to 365 pmol bt-HRP/mg beads) was built 
(Figure 2). As observed, a minimum bt-HRP concentration of 90 pmol/mg of beads (4.5 nM; 
inflexion point of the curve) is required to saturate the beads. In this sense, to ensure the 
complete saturation of beads and a constant maximum signal (no depletion in bt-HRP in any 
conditions), we decided to work with a three times more concentrated solution of bt-HRP (300 
pmol/mg, 15 nM).  
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Once these parameters were fixed, we evaluated the influence of incubation time. Thus, we 
saturated beads with bt-HRP at four different incubation times: 30, 60, 90 and 120 min. Despite 
no significant differences in the chemiluminescent signal were observed, the shorter incubation 
times led to less precise signal with a CV of 8% while for the rest of assayed times the CV 
remains constant at 4%. Therefore 1 hour was selected as the minimum incubation time required 
for a robust maximum signal.  
 
Grafting yield and Stability 
In order to achieve a precise amount of biomolecules grafted on the beads, the yield of grafting 
of MB with various molecules was evaluated. For this purpose, consecutive grafting procedures 
of MB with biotinylated molecules were carried out. After the first grafting, the supernatant was 
recovered and used again in a fresh MB suspension. This allows the molecules that have not 
been bound during the first grafting procedure to graft during the second grafting procedure. The 
Sat. rate of MB of each step was estimated with the bt-HRP assay. 
Figure 3 shows percentages of saturation after the two grafting procedures of MB for three 
model molecules (biotin, bt-VEGF95 and bt-BSA) at different concentrations. As observed in 
Figure 3a, before reaching the total saturation of beads (600 pmol biotin/mg of beads), biotin 
molecules were totally bound onto the MB during the first grafting. Indeed, the Sat. rate were 
negligible after the second grafting procedure. In addition, it is interesting to note that with 800 
pmol of biotin, corresponding to 200 pmol above the saturation, the resulting second Sat. rate 
(40%) is the same than the Sat. rate obtained with 200 pmol of biotin in the first grafting, 
indicating a yield of grafting of 100%.  
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In the case of bigger molecules, such as bt-VEGF95 (MW = 28 kDa, Figure 3b) and bt-BSA 
(MW = 66 kDa, Figure 3c), a small amount of ligand remained unbound after the first grafting as 
indicated by the small percentage of saturation observed after the second grafting at 
concentrations below the total saturation. For example, at 200 pmol/ mg of beads of bt-VEGF95, 
15% of Sat. rate was obtained during the second grafting. The same behavior is observed for bt-
BSA. Thus, for bt-VEGF95 and bt-BSA the yield of the grafting of MB was assessed around 
80%. The observed difference in term of yield of grafting between biotin and bigger biotinylated 
molecules may be due to biotin accessibility. Indeed, we can assume that biotin covalently 
bounded to a folded protein may be less available because of steric hindrance. 
On the other hand, the possibility of displacement of the biotin or other biotinylated molecule 
grafted onto MB by bt-HRP molecules during the incubation of grafted beads was evaluated. For 
that purpose, bt-HRP assay was carried out in both non-grafted MB and biotin-saturated beads 
(900 pmol biotin/mg beads) using a range of different concentrations of bt-HRP (from 0.05 nM 
to 18 nM). As observed in Figure S1 (see in the Supporting Information), biotin-saturated beads 
exhibited the same behavior at any bt-HRP concentration assessed with a mean Sat. rate of 
100%, showing CV below 4%. Additionally, Sat. rate of MB grafted with biotin at different 
concentration (from 0 to 900 pmol biotin/mg beads) was assessed at four different bt-HRP 
concentrations (2.5, 5, 10 and 15 nM, Figure S2). As observed, there are no differences in the 
saturation obtained for each biotin-grafted beads with regard to bt-HRP concentrations used for 
incubation. Therefore, taking all of the above into account, we have corroborated that no 
displacement of grafted molecules onto beads takes place during the 1h incubation time with the 
bt-HRP, even at high concentration (15 nM). These results are consistent with the high affinity 
constant of the streptavidin-biotin interaction24. 
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Beads saturation and molecular weights 
Once determined the yield of grafting and assessed the robustness of the assay regarding 
displacement by bt-HRP, the grafting of MB with different biotinylated molecules at different 
molecular weights was evaluated. Moreover, the Sat. rate obtained by the assay was correlated to 
the ligand surface density. 
First, a set of different biotinylated molecules that covered a wide range of molecular weights 
was selected to assess the grafting of MB. In addition, these molecules also present different 
chemical structures (i.e. small organic molecules, peptides, proteins and antibodies). Biotin (244 
Da) was selected as the smallest molecule since free biotin molecules should occupy all available 
streptavidin sites on the surface of the MB in the saturation condition, whereas a biotinylated 
antibody of 150 kDa (immunoglobulin G, IgG) was selected as the biggest molecule to be 
evaluated. Different biotinylated molecules such as bt-peptide A (1951 Da), bt-VEGF95 (28 000 
Da), bt-VEGF165 (40 000 Da) and bt-BSA (66 000 Da) were also used to explore the predictive 
power of the bt-HRP assay. 
Figure S3 displays the Sat. rate of grafted MB for different biotinylated molecules on a wide 
range of concentrations (0 to 1000 pmol molecule/mg beads). As it can be observed, the 100% of 
saturation of MB was reached at different concentrations depending on the biotinylated molecule 
and, particularly, depending on its molecular weight. In particular, the Sat. rate profile for all 
biotinylated molecules exhibits two well-differentiated ranges: one range of linearity in which 
the saturation of MB increases as a function of the concentration of the molecule until reaching 
the 100% of saturation and another flat and constant range in which the concentration of 
molecule used for the grafting leads to the total saturation of beads (Figures 4 and S4). The 
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concentration range assayed in the bt-HRP assay, the saturation concentration as well as the 
linear range for each biotinylated molecule are all collected in Table 1. 
As it can be observed, the saturation of MB using the smallest molecule (biotin) was obtained 
using a concentration of 605 ± 10 pmol biotin/mg beads, while using the biggest one (bt-Goat 
IgG) was obtained with a concentration of 70 ± 2 pmol bt-GoatIgG/mg beads. Interestingly, 
these results are in perfect agreement with those reported for typical binding capacities of one 
mg of commercial MB23: between 650 and 900 pmol/mg for free biotin and ~10 g/mg (~67 
pmol/mg) for a biotinylated antibody. 
Considering all the biotinylated molecules whose molecular weights vary from 200 Da to 150 
kDa, we can confirm that the saturation concentration is correlated to the molecular weight 
(Figures 4 and S4, and Table 1). In other words, the amount of biotinylated molecule which is 
necessary to saturate MB decreases as the molecular weight of the molecule increases likely due 
to steric hindrance effects.  
 
Determination of the ligand surface density on streptavidin-magnetic beads 
The proposed bt-HRP assay allows evaluating the different behaviors and Sat. rate obtained 
when grafting MB. However, percentage of saturation of beads is a relative parameter. The 
ligand surface density () is a stronger factor as it is an absolute parameter. Such ligand surface 
density on the MB was determined using the equation 2, which is based on the equation already 
reported by Elzey et al.11 and Ndolomingo et al.15, considering that yield of grafting is 100%: 
 
𝝈𝒄𝒂𝒍𝒄 = (
𝒎𝒎𝒐𝒍𝒆𝒄𝒖𝒍𝒆
𝒎𝒃𝒆𝒂𝒅
) (
𝑵𝑨 𝝆𝒃𝒆𝒂𝒅 𝒅𝒃𝒆𝒂𝒅
𝟔 𝑴𝑾𝒎𝒐𝒍𝒆𝒄𝒖𝒍𝒆
)         Equation 2 
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where σcalc is the calculated ligand surface density; mmolecule and mbead are the biotinylated 
molecule mass and the magnetic bead mass, respectively; NA is the Avogadro constant; ρbead and 
dbead are the density and the diameter of the spherical MB, respectively; and MWmolecule is the 
molecular weight of the biotinylated molecule used in the grafting. 
Consequently, we were able to establish the correlation between the ligand surface density and 
the Sat. rate of these grafted beads. In this context, Figure S5 shows linear relationships that 
relate the Sat. rate of beads (until achieving the 100% of the bead saturation) with the ligand 
surface density for different concentrations of each biotinylated molecule. Furthermore, the 
ligand surface density at 100% of saturation of beads was calculated for the free biotin and the 
five biotinylated molecules assessed. Ligand surface densities obtained in terms of number of 
molecules/m2 were the following: 266·103 ± 4·103 for biotin (244 Da), 234·103 ± 6·103 for bt-
peptide A (1951 Da), 169·103 ± 6·103 for bt-VEGF95 (28 kDa), 76·10
3 ± 2·103 for bt-VEGF165 
(40 kDa), 38·103 ± 2·103 for bt-BSA (66 kDa), and 27·103 ± 4·103 for bt-Goat IgG (150 kDa). 
These results not only evidence the different surface packing of molecules, but also confirm the 
fact that the ligand surface density on MB decreases as the molecular weight of biotinylated 
molecules increases, leading to a steric saturation of beads as the molecule size is higher. It is 
also interesting to note that evolution of ligand surface density with molecular weight is not 
linear (see Figure S-6 in the Supporting Information) confirming the importance of the volume 
occupied by the molecule and consequently steric hindrance. 
 
Control and validation of the developed methodology 
In previous sections, we have demonstrated that the developed bt-HRP assay allows 
establishing linear relationships between the Sat. rate of MB or ligand surface density with 
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concentrations of biotinylated molecules used for the grafting of beads. In this context, it would 
be interesting to verify if those linear relationships can be used to predict the Sat. rate of grafted 
beads with any other biotinylated molecules within the molecular range assayed. 
In a first step, two others biotinylated molecules, a bt-peptide (bt-peptide B) of 1895 Da and a 
bt-IgG (bt-anti hEndoglin IgG) of 150 kDa, were selected. The idea was to prove that we are able 
to estimate the necessary concentration to obtain a desired percentage of saturation of beads 
based on the previous experimental results obtained for similar molecules (respectively bt-
peptide A and bt-Goat IgG). Figures 4f and S4b were respectively used to determine the required 
concentrations of each molecule to obtain 30%, 50% and 100% saturation of MB. 
Table 2 collects interpolated and experimentally obtained saturation results at different 
concentrations. As can be seen, the Sat. rate experimentally obtained by the bt-HRP assay for 
both biotinylated molecules fits very well with the saturation percentages interpolated from the 
linear equations for each molecular weight.  
In a second step, we estimated the robustness of our predictive assay with a biotinylated 
molecule with any molecular weight between 0.2 and 150 kDa. Indeed, using results from 
Figures 4 and S4, a correlation between concentration of biotinylated molecules and molecular 
weight can be established. Specifically, two linear relationships (Cmolecule function of MWmolecule) 
for achieving half-saturation (50%) and saturation (100%) of the MB were obtained (Figure 5). 
Adequate correlation coefficient is obtained in the range between biotin (244 Da) and bt-BSA 
(66 kDa). The bt-Goat IgG (150 kDa) was excluded due to its huge difference in molecular 
weight in comparison to the other biotinylated molecules and the bt-HRP. However, the linear 
relationship of the bt-Goat IgG (Figure 4f) could be used to determine the necessary 
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concentration of any bt-antibody to obtain the desired saturation of beads with this type of 
molecule. 
In order to validate the potential of these linear correlations, two biotinylated molecules were 
assessed: a small bt-polymer (844 Da) and the bt-TNFα protein (51 kDa). Required 
concentrations to achieve 50% and 100% of saturation with these two molecules were predicted 
simply using their corresponding molecular weights and previously obtained equations (Figure 
5). As shown in Table 3, the feasibility of this methodology was demonstrated as the Sat. rate 
obtained experimentally by the bt-HRP assay carried out using the calculated concentrations, 
were statistically undistinguishable from the percentages of saturation intended, that is, 50% and 
100% of saturation. 
Finally, a biotinylated single stranded oligonucleotide of 80 nucleotides (~25 kDa) was also 
evaluated. Again, required concentrations of bt-oligonucleotide to obtain 50% and 100% of 
saturation were determined (185 and 410 pmol/mg beads, respectively). However, percentages of 
saturation obtained experimentally (Table 3) were both around 100 %. In this case experimental 
and intended values are not in agreement with the predictive values of the assay. Nevertheless, 
these results are corroborated by the binding capacity announced in the commercial datasheet 
(200 pmol/mg beads)23, showing the performance of the test to characterize the grafting process. 
Particular behavior may be explained by the fact that DNA is a highly negatively charged 
molecule which can induce additional repulsions on the surface of the MB. In addition, it has 
also been reported that the binding capacity for oligonucleotides is inversely related to their 
molecule size (number of bases), being reduced for large DNA fragments25. 
 
CONCLUSIONS 
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In response to the need of controlling particle functionalization in terms of stoichiometry, 
saturation and ligand surface density, we present a new rapid, easy and cost-effective assay for 
the determination of the saturation grade of MB. This saturation rate can be easily correlated 
with a more general characterization parameter such as surface ligand density. Of course, in 
order to fully characterize the functionalized particle, it would be also recommended to evaluate 
the ligand functionality after grafting by a complementary test (e.g. immunoassay). Please note 
that both parameters (ligand density and ligand function) are related since saturation rate may 
influence the ligand functionality (i.e. crowded ligand at the surface may have negative impact 
on its functionality). Of course, such relationship should be studied for each specific case as it is 
species specific. However, it should be mentioned here that there are many examples in the 
bibliography where such functionalized particles are grafted with different molecules while 
keeping their activity (i.e. recognition capability).REF  
In addition of this control issue, it is remarkable to emphasize the predictive power of the assay 
that allows proceeding easily to controlled beads grafting with any biotinylated molecule in a 
molecular range from 1 to 150 kDa, except for the special case of DNA. These control and 
predictive features will help the users to efficiently design the functionalized beads for further 
applications. Nevertheless, the predictive model was built using smaill molecules, linear peptides 
and polymers and globular proteins (antibodies, enzymes…). Of course, complementary studies 
with different types of biotinylated molecules (e.g. fibrillar proteins) could be performed in order 
to further generalize the predictive value of the assay.  
Finally, this assay can be considered as a general approach for the saturation rate determination 
of any streptavidin functionalized particle or support by adapting the protocol. For example, 
centrifugation or ultrafiltration can be employed as purification steps when non-magnetic 
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particles are used. In the case that nanoparticles show native optical properties, spectral 
interferences (energy transfer, spectral overlapping, etc) should be considered and the 
methodology accordingly modified (e.g. change of the enzyme substrate). 
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FIGURES  
Figure 1. Schematic representation of the streptavidin MB grafting process and the bt-HRP 
chemiluminescent test. 
 
Figure 2: Saturation curve of streptavidin MB with bt-HRP 
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Figure 3. Saturation rate (%) obtained after grafting (red points) and second grafting (black 
points) of MB with different concentrations of a) biotin, b) bt-VEGF95 and c) bt-BSA. n=4, 
uncertainties correspond to 1SD. 
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Figure 4. Saturation curves (a,c,e) and linear relationships (b,d,f) of the grafted MB at different 
concentrations of biotinylated molecules: a,b) biotin (black); c,d) bt-VEGF95 (green); and e,f) bt-
Goat IgG (orange). n=3, uncertainties correspond to 1SD. (continues in Figure S-4 in the 
Supporting Information) 
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Figure 5. Linear relationship obtained when the influence of the molecular weight of the 
molecule used for the bead grafting on the concentration of the biotinylated molecule was 
studied for achieving the 50% (black) and 100% (red) of the bead saturation. n=3, uncertainty 
corresponds to 1SD. 
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TABLES.  
Table 1. Concentration range assayed, linear range and saturation concentration obtained in the 
bt-HRP assay for various biotinylated molecules with different molecular weights. n=3, 
uncertainties correspond to 1SD. 
Biotinylated 
molecule 
MW 
(kDa) 
Concentration 
range assayed 
(pmol/mg beads) 
Linear range 
(pmol/mg beads) 
Saturation 
concentration 
(pmol/mg beads) 
biotin 0.244 0 - 1000 180 - 600 605 ± 10 
bt-peptide A 1.951 0 - 900 90 - 600 625 ± 15 
bt-VEGF95 28 0 - 800 30 - 400 440 ± 15 
bt-VEGF165 40 0 - 500 10 - 180 190 ± 5 
bt-BSA 66 0 - 600 30 - 90 100 ± 5 
bt-Goat IgG 150 0 - 180 5 - 60 70 ± 2 
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Table 2. Saturation rate (%) intended and experimentally obtained for two biotinylated 
molecules (bt-peptide B and bt-anti hEndoglin IgG) using the bt-HRP assay and concentrations 
interpolated by means of equations of linear relationships obtained for bt-peptide A (1951 Da) 
and bt-Goat IgG (150 kDa), respectively. n=3, uncertainties correspond to 1SD. 
Biotinylated molecule 
MW 
(kDa) 
Concentration 
interpolated * 
(pmol/mg beads) 
Sat. rate intended 
(%) 
Sat. rate obtained 
(%) 
bt-peptide B 1.895 
160 30 34 ± 7 
295 50 58 ± 4 
625 100 98 ± 1 
bt-IgG 
(bt-anti hEndoglin 
IgG) 
150 
5 30 26 ± 4 
25 50 52 ± 4 
70 100 99 ± 1 
*Equation used for bt-peptide B: Sat. rate = 0.1496 · [bt-peptide] + 6.135. 
Equation used for bt-anti hEndoglin IgG: Sat. rate = 1.1434 · [bt-IgG] + 22.075. 
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Table 3. Saturation rate (%) intended and experimentally obtained for three biotinylated 
molecules (bt-polymer, bt-TNFα protein and bt-oligonucleotide) using the bt-HRP assay and 
concentrations interpolated by means of equations of linear relationships relating molecular 
weights (MW) of biotinylated molecules with concentrations of these molecules for achieving 
50% and 100% of the bead saturation. n=3, uncertainties correspond to 1SD. 
Biotinylated 
molecule 
MW 
(kDa) 
Concentration 
interpolated * 
(pmol/mg beads) 
Sat. rate 
intended   
(%) 
Sat. rate obtained   
(%) 
bt-polymer 0.844 
300 50 51 ± 6 
615 100 96 ± 7 
bt-TNFα protein 51 
65 50 48 ± 14 
195 100 102 ± 4 
bt-oligonucleotide 
~25 
(80 
nucleotides) 
185 50 100 ± 1 
410 100 100 ± 2 
 
*Equation used for achieving 50% of the bead saturation: [bt-molecule] = -0.0047 · MW + 
304.23. 
Equation used for achieving 100% of the bead saturation: [bt-molecule] = -0.0084 · MW + 
623.58. 
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